Does Tesamorelin work for fat reduction? Clinical evidence and expected effects

Clinical evidence consistently demonstrates measurable fat loss during tesamorelin therapy. In a placebo-controlled study conducted by Falutz J et al. (2007), HIV-positive individuals taking 2 mg of tesamorelin daily for 26 weeks achieved approximately a 15% reduction in visceral abdominal fat compared to placebo [4]. Participants also showed a reduction in waist circumference and improvements in triglyceride levels and cholesterol profiles without a significant deterioration in blood sugar control.

Larger Phase III clinical trials confirmed these results. In a multicenter pooled analysis involving 806 participants, Falutz J et al. (2010) reported an average reduction in visceral fat of approximately 15.4% after 26 weeks of tesamorelin therapy [5]. The researchers also observed improvements in waist circumference, abdominal appearance, and several metabolic markers. Importantly, participants who continued treatment maintained the fat-reduction benefits for up to 52 weeks, whereas those who discontinued therapy regained visceral fat relatively quickly.

Tesamorelin has also demonstrated benefits in reducing hepatic fat associated with abdominal obesity and metabolic disorders. In a randomized clinical trial conducted by Stanley TL et al. (2014), tesamorelin significantly reduced both visceral abdominal fat and hepatic fat in HIV-positive individuals with excessive abdominal fat accumulation [6]. Hepatic fat refers to fat stored within the liver. Participants receiving tesamorelin experienced a reduction in deep abdominal fat, while an increase was observed in the placebo group. Similar results were reported in a multicenter study by Stanley TL et al. (2019), where tesamorelin reduced hepatic fat by approximately 37% relative to baseline in individuals with HIV-associated non-alcoholic fatty liver disease (NAFLD) [7].

Further research also suggests that tesamorelin improves overall body composition rather than just lowering scale weight. Adrian S et al. (2019) demonstrated that individuals responsive to tesamorelin treatment experienced increased muscle area and muscle density, while simultaneously decreasing abdominal fat [8]. Muscle density refers to the quality and composition of muscle, suggesting that tesamorelin may help preserve or improve lean tissue while reducing harmful visceral fat.

The amount of fat lost while using tesamorelin may vary from person to person; however, studies consistently show clinically significant reductions in visceral fat over approximately 3 to 6 months of daily therapy. In many clinical trials, the reduction in visceral fat ranged from approximately 11% to 18%, depending on the duration of treatment and individual metabolic characteristics [4,5,9]. Participants with metabolic syndrome, elevated triglyceride levels, obesity, and increased cardiovascular risk often achieved greater reductions in visceral fat during therapy [10].

Tesamorelin appears to be particularly effective at reducing visceral abdominal fat rather than causing overall weight loss. Unlike many weight loss therapies, which can reduce both fat and muscle mass, tesamorelin preferentially targets deep abdominal fat while helping to preserve healthier subcutaneous fat and lean body mass [3–6]. Clinical studies have also demonstrated improvements in waist circumference, trunk fat, liver fat, triglyceride levels, and adiponectin [5,11]. Adiponectin is a hormone involved in insulin sensitivity and metabolic regulation.

Research also indicates that continuing treatment may be important for maintaining effects. Long-term studies have shown that participants who discontinued tesamorelin therapy often regained visceral abdominal fat over time, while continuing therapy maintained abdominal fat reduction and improved metabolic parameters [5,9]. This suggests that tesamorelin's effect is dependent on continuous stimulation of the body's natural GH pathways.

Generally speaking, current clinical evidence shows that tesamorelin effectively reduces visceral abdominal fat and improves body composition, particularly in individuals with HIV-associated lipodystrophy and fatty liver disease. Human studies consistently demonstrate reductions in belly fat, waist circumference, liver fat, and metabolic risk markers, while preserving lean body mass and maintaining relatively stable glucose metabolism [4–11].

Disclaimer

The content is for educational and scientific information purposes only. It should not be interpreted as medical advice, diagnosis, or therapeutic recommendations. Tesamorelin is a prescription medication primarily approved for the treatment of HIV-associated lipodystrophy. Therapies affecting growth hormone and metabolic pathways require medical supervision, laboratory monitoring, and individual clinical assessment by a qualified healthcare professional.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: NCBI Bookshelf: Tesamorelin Overview
2. PubChem. (2025). Tesamorelin Compound Summary. National Center for Biotechnology Information. Available at: PubChem Tesamorelin Summary
3. Falutz J, Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
4. Falutz J, Potvin, D., Mamputu, J. C., Assaad, H., Zoltowska, M., Michaud, S. E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322. https://doi.org/10.1097/QAI.0b013e3181cbdaff
5. Falutz J, Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
6. Stanley TL, Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
7. Stanley TL, Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
8. Adrian S, Scherzinger, A., Sanyal, A., et al. (2019). Growth hormone-releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. The Journal of Frailty & Aging, 8(3), 154–159. https://doi.org/10.14283/jfa.2018.45
9. Falutz J, Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
10. Mangili A, Falutz, J., Mamputu, J. C., Stepanians, M., & Hayward, B. (2015). Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS ONE, 10(10), e0140358. https://doi.org/10.1371/journal.pone.0140358
11. Stanley TL, Falutz, J., Marsolais, C., et al. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 54(11), 1642–1651. https://doi.org/10.1093/cid/cis251